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Abstract
Background: Antimicrobial resistance among bacteria pathogens is a world-wide issue. The antimicrobial susceptibility patterns of
common pathogenic bacteria are essential to guide empirical and pathogen-specific therapy; unfortunately, these data are scarse in
Cameroon.
Objective: To determine the antimicrobial susceptibility patterns of Gram-negative bacilli isolated in Yaounde Central Hospital
Laboratory of Bacteriology.
Methods: Gram-negative bacilli isolates (n = 505), obtained from a wide range of clinical specimens (urine, pus and blood) in
Yaoundé Central Hospital Laboratory of Bacteriology between March 1995 and April 1998, were evaluated for resistance to antibiotics
(amoxicillin, amoxicillin/clavulanate, piperacillin, cefazolin, cefoxitin, cefotaxime, ceftazidime, aztreonam, imipenem, gentamicin,
tobramicin, ofloxacin and trimethoprim/sulfamethoxazole) by the Kirby-Bauer disk diffusion method.
Results: High rates of resistance were found in most of the bacteria studied. Resistance to all isolates was mostly observed for
amoxicillin (87%), piperacillin (74%) and trimethoprim/sulfamethoxazole (73%). Susceptibilities to third generation cephalosporins
(cefotaxime, ceftazidime) and monobactame (aztreonam) were = 91% for Escherichia coli, = 71% for Klebsiella spp., = 98% for Proteus
mirabilis, = 50% for Enterobacter spp. and Citrobacter spp. Pseudomonas aeruginosa was less susceptible to cefotaxime (2%) and aztreonam
(33%), and highly susceptible to ceftazidime (72%) whereas Acinetobacter baumannii was highly resistant to aztreonam (100%), to
cefotaxime (96%) and cetazidime (62%). Imipenem (98%) was the most active antibiotic followed by the ofloxacine (88%).
Susceptibility of all isolates to gentamicin was 67%.
Conclusion: These results indicate that surveillance to antimicrobial resistance in Cameroon is necessary to monitor microbial
trends, antimicrobial resistance pattern, and provide information for choosing empirical or direct therapy to physicians.
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Gram-negative bacilli are the most important bacterial
pathogen, and are generally resistant to antibiotics 
1, 2, 3
.
Monitoring for antimicrobial resistance in this group is
important because resistance has been reported to be
associated with increased patient morbidity and mortality,
and contributed to escalating healthcare cost 
4
.
Antimicrobial resistance is increasing in many bacteria
and is a worldwide problem 
5, 6
.
The antimicrobial susceptibility patterns of
common pathogenic bacteria are essential to guide
empirical and pathogen-specific therapy. This informa-
tion is also important for rational policies against
antimicrobial resistance. Unfortunately, in many
developing countries, these data are scarce because of
dwindling resources. In Cameroon, data on antimicrobial
resistance among bacterial pathogens are sparse. In an
effort to determine the extent of antimicrobial resistance
amongst Gram-negative bacilli isolated in Yaounde Cen-
tral Hospital Laboratory of Bacteriology, we conducted a
survey of 505 Gram-negative bacilli and measured their
in vitro susceptibility to antimicrobial agents.
Materials and Methods
Between April 1995 and March 1998, all the aerobic
Gram-negative bacilli isolated in the laboratory of
bacteriology of Yaounde Central Hospital were collected
prospectively. The isolates studied were confined to
unrelated first isolates from different patients, and did
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not include multiple isolates from the same patient.
Isolates were recovered from urine, pus and blood cul-
tures and identified by standard laboratory technique
methods 
7
 and confirmed by Api 20E (BioMerieux,
France).
The antimicrobial susceptibility test was
determined by the Kirby-Bauer disk diffusion method
following the National Committee of Clinical Laboratory
Standards (NCCLS) for agar diffusion tests
8
. The
antibiotics tested were amoxicillin (30µg), amoxicillin/
clavulanate (20/10 µg), piperacillin (100 µg), imipenem
(10 µg), cefazolin (30 µg), cefoxitin (30 µg), cefotaxime
(30 µg), ceftazidime (30 µg), aztreonam (30 µg),
gentamicin (10 µg), tobramycin (10 µg), ofloxacin (5
µg) and trimethoprim/sulfamethoxazole (1.25/23.75
µg). The following American Type Culture Collection
(ATCC) microorganisms were tested each time
susceptibility testing was performed: Escherichia coli
ATCC 25922 and Pseudomonas aeruginosa ATCC 27853.
Test results were only validated in the cases where inhi-




Data were analyzed using Whonet 4 (World
Health Organization, Geneva, Switzerland) and resistance
included combined, intermediary and resistance results.
Results
A total of 505 aerobic isolates were collected, identified,
and tested. Enterobacteriaceae (E. coli, Klebsiella spp.,
Proteus spp., Enterobacter spp., and Citrobacter spp.)
represented 79.8% of the isolated strains. Non
fermentative Gram negative bacilli (Pseudomonas spp. and
Acinetobacter baumannii) represented 20.2%. The sour-
ces of the isolates are shown in table 1.
Table 2 summarizes the results of susceptibility
tests of Gram-negative bacilli studied against antimicrobial
agents. Imipenem (98% susceptible (S)) was the most
active agent against all pathogens tested followed by
ofloxacine (88% S) and ceftazidime (86% S). Amoxicillin
(13% S), piperacillin (26% S), trimethoprim/
sulfamethoxazole (27% S), cefazolin (30% S) and
amoxicillin/clavulanate (37% S) were the least active
agents.
Against E. coli, susceptibility rates range from
15% (amoxicillin, piperacillin) to 99% (imipenem). The
least active agents against Klebsiella spp. were amoxicillin
(0% S) followed by piperacillin (10% S) and
trimethoprim/sulfamethoxazole (15% S). The most ac-
tive agents were imipenem (93% S) and ofloxacin (98%
S). Proteus mirabilis was the most sensitive pathogen of all
microorganisms. The susceptibility rate ranged from 40
% (amoxicillin) to 100% (imipenem, ceftazidime and
aztreonam). Concerning Enterobacter spp., only two
antimicrobial agents had activity rate >80% ((ofloxacin
(98%) and imipenem (97%)). For Citrobacter spp. the
most active agents were imipenem (96% S) followed by
ceftazidime (76% S) and ofloxacin (73% S). Only 94%
of P. aeruginosa isolates were susceptible to imipenem, as
compared to 100% observed for A. baumannii. However,
72% of P. aeruginosa were susceptible to ceftazidime as
compared to only 38 % of the A. baumannii. All the A.
baumannii isolates tested were resistant to aztreonam.
Table 1. Distribution (%) of bacterial species by clinical specimen
Organism Clinical specimen
Pus Urine Blood
Escherichia coli 33.7 65.0   1.3
Klebsiella spp. 43.3 44.3 12.4
Proteus mirabilis 58.0 42.0   0.0
Enterobacter spp. 47.5 42.5 10.0
Citrobacter spp. 50.0 50.0   0.0
Indole positif Proteus spp. 50.0 43.8   6.2
Pseudomonas aeruginosa. 71.6 22.4   6.0
Acinetobacter baumannii 54.2 25.0 20.8
Pseudomonas spp. 70.0 10.0 20.0
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Table 2. Susceptibility (%) of Gram negative bacilli studied
                      All E. coli     Klebsiella     P. mirabilis   Enterobacter   Citrobacter     Indole           P. aeruginosa   A. baumannii  Pseudomonas spp.
                     isolates               spp.         spp.            spp.             positif
               Proteus spp.
                    n=505 n=163  n=97        n=62        n=40           n=26          n=16      n=67            n=24        n=10
Isolates
Antibiotic   %S %S         %S           %S         %S              %S                %S        %S              %S         %S
Amoxicillin   13 15         0           40        0                 0               0        /                 /         /
Amoxicillin   37 43         35             69        0                  40               0                  /                  /         /
/ clavulanate
Piperacillin    26 15        10          53        35                19               56       46                4         50
Cefazolin       30 41        24           48        0                  4               0       /                  /         /
Cefoxitin       74 91         84           97        5                  8               31       /                  /         /
Cefotaxime    67 91         71             98        60               50               94       2                  4        30
Ceftazidime    86 95         88           100        80               76               94       72                38        70
Aztreonam     73 92         75           100        65                69               88       33                0        20
Imipenem      98 99         99           100        97                96               94      94                100        100
Gentamicin    67 84         65           68        60                58               50       49                58         50
Tobramycin    57 /a          /            /        /                  /               /       56                69         50
Ofloxacine    88 91         98           98        98                73               82       66                70         90





This study represents an extensive examination of the
susceptibility patterns of Gram negative bacilli isolated
in the laboratory of bacteriology of Yaounde Central
Hospital. Our isolates represente both nosocomial and
community acquired-pathogens, and were collected
from April 1995 to March 1998. The results of this study
show that in general, high rate of resistance occurs among
Gram-negative bacilli to commonly used antibiotics
(penicillins, first generation cephalosporin and
trimethoprim/sulfamethoxazole).
For E. coli and Klebsiella spp., the rate of
resistance to third generation cephalosporins and other
â-lactam antibiotics can be explained by the high pro-
duction of penicillinase and the production of extended
spectrum â-lactamase 3, 9. However, the rate of this
resistance is high compared to those reported in
developed countries 10, 11.
Enterobacter spp. and Citrobacter spp. were highly
resistant to ceftazidime, cefotaxime and aztreonam.
Similar results were observed in Cairo (Egypt) by El
Kholy et al., 2003 12 and in developed countries 10, 13.
This resistance could be explained by the high produc-
tion of cephalosporinase and the production of extended
spectrum â-lactamase by these strains 3, 9.
Our data showed that P. mirabilis is the most
sensitive species. The susceptibility rates of this species
to all antibiotics tested are compared to those observed
in developed countries 10, 11.
Non-â-lactam antibiotics resistance rates among the
species of the Enterobacteriaceae family studied were com-
parable to the reported rates in other parts of developing
countries 14, 15, but higher than those reported in
developed countries 10, 13. The combination of
trimethoprime/sulfamethoxazole is extensively used in
Africa owing to its antimicrobial spectrum of activity,
and its low cost 16. In addition, extended spectrum â-
lactamase production is usually associated with resistance
to non-â-lactam antibiotics such as aminoglycosides,
fluoroquinolones and trimethoprim/sulfamethoxazole
17.
The susceptibility rates of isolates of P. aeruginosa
and A. baumannii in this study to all antibiotics tested
except for imipenem, were low compared to those
reported in developed countries 10, 18, 19 and similar to
those observed in Egypt 12 and in West Africa 15.
In conclusion, our study suggests the high rates
of antimicrobial resistance among Gram-negative bacilli.
The presence of E. coli and Klebsiella spp. isolates resistant
to third generation cephalosporin suggests the impor-
tance of monitoring this phenotype. Particularly alarming
is the appearance of low level imipenem resistance among
different species of Gram negative bacilli studied. The
results of this study indicate that more resources should
be allocated to encourage good antibiotics utilization and
practice. In addition, to provide information for choosing
either empirical or direct therapy to physicians, sur-
veillance to antimicrobial resistance is necessary.
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